November 2, 1993European Heart Journal
New class III antiarrhythmic drugs
Key result
New class III antiarrhythmic drugs show efficacy against re-entrant arrhythmias but carry a substantial proarrhythmic risk, particularly torsade de pointes, necessitating careful clinical evaluation.
Why the study?
Do new class III antiarrhythmic drugs suppress arrhythmias and prevent arrhythmic sudden death?
Population
Patients with re-entrant supraventricular and ventricular arrhythmias, or postinfarction arrhythmias
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Warrants individualized risk assessment before use; leaves open net benefit versus torsade risk in large trials.
Structured PICO
Do new class III antiarrhythmic drugs suppress arrhythmias and prevent arrhythmic sudden death?
P
Population
Patients with re-entrant supraventricular and ventricular arrhythmias, or postinfarction arrhythmias
I
Intervention
New class III antiarrhythmic drugs
O
Outcome
Suppression of arrhythmias and prevention of arrhythmic sudden death
New class III antiarrhythmic drugs show promise in treating supraventricular and ventricular arrhythmias but require careful clinical evaluation due to the risk of torsade de pointes.
Limitations
- Substantial proarrhythmic tendency associated with these drugs, mainly in the form of torsade de pointes
Cite This Study
Katritsis et al. (1993) conducted a review in Arrhythmias. New class III antiarrhythmic drugs was evaluated. New class III antiarrhythmic drugs show efficacy against re-entrant arrhythmias but carry a substantial proarrhythmic risk, particularly torsade de pointes, necessitating careful clinical evaluation.